ISO 9001:2015 and ICH GCP E6(R3): Two Standards, One Language of Quality in Clinical Research

Why these standards matter

In today’s clinical research landscape, quality is not optional — it is the foundation of trust between sponsors, CROs, regulators, and, ultimately, patients. Two major frameworks set the tone:

• ISO 9001:2015, the world’s most widely adopted quality management standard, and
• ICH GCP E6(R3), the latest revision of Good Clinical Practice, finalized in 2025.

Although designed for different purposes, these standards increasingly speak the same language of quality. For CROs, the real opportunity lies not in choosing between them, but in integrating both into a unified quality management system.

ISO 9001:2015 – the universal foundation

ISO 9001:2015 is a broad quality management standard applicable across industries. It emphasizes:

• Risk-based thinking in all processes
• Leadership commitment and clear responsibilities
• A process-driven approach with documented workflows
• Competence and training for staff
• Continuous improvement through the Plan–Do–Check–Act (PDCA) cycle

For CROs, ISO 9001 provides the backbone: governance, transparency, and a culture of quality that extends across all operations.

ICH GCP E6(R3) – the clinical research framework

GCP E6(R3), the most comprehensive GCP update since 2016, reflects the realities of modern trials:

• Quality-by-Design (QbD): embedding quality into protocol design
• A six-step risk management cycle (identify, assess, control, communicate, monitor, report)
• Technology-neutral guidance for eConsent, wearables, EHR integration
• Clear role definitions for sponsors, CROs, investigators, IRBs/IECs
• Stronger emphasis on data integrity, traceability, and transparency (ALCOA+)

Where ISO offers breadth, GCP provides depth — ensuring clinical trials are both scientifically valid and ethically sound.

Why integration matters for sponsors

The message for sponsors is clear: a CRO that integrates ISO 9001:2015 and GCP E6(R3) delivers stronger, more reliable results.

• Higher compliance assurance: quality and GCP are not siloed but aligned.
• Proactive risk mitigation: issues are identified early, reducing costly deviations.
• Operational efficiency: one system avoids duplication of audits and processes.
• Transparent accountability: clear visibility into roles and responsibilities.
• Future resilience: readiness for decentralized trials, digital endpoints, and evolving regulatory expectations.

The bottom line

ISO 9001:2015 and ICH GCP E6(R3) represent two sides of the same coin: one offers the broad framework of quality governance, while the other provides the clinical precision and ethical safeguards that define modern trials. Standing alone, each is valuable. But when woven together into a unified system, they create a powerful foundation for excellence in clinical research.

At Cromos Pharma, this integration is not a future aspiratio, it is already part of our operational DNA. Our ISO 9001:2015–certified quality management system is fully aligned with the principles of ICH GCP E6(R3), ensuring that every trial we manage is conducted with the highest standards of consistency, integrity, and patient protection.

For CROs, such integration is no longer optional , it is the benchmark that separates true quality partners from the rest. And for sponsors, choosing Cromos Pharma means more than smoother operations: it means working with a partner who speaks this “one language of quality” fluently, delivering stronger compliance, faster timelines, and the assurance that every result will stand up to both regulatory scrutiny and the ultimate test of patient trust.

Looking ahead, do you see ISO and GCP evolving into a single “language of quality” in clinical research — or will they remain parallel systems? Share your perspective in the comments.